130 related articles for article (PubMed ID: 10848872)
1. Genetic immunotherapy of established tumours with adenoviral vectors transducing murine interleukin-12 (mIL12) subunits in a rat medullary thyroid carcinoma model.
Zhang R; DeGroot LJ
Clin Endocrinol (Oxf); 2000 Jun; 52(6):687-94. PubMed ID: 10848872
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy of a rat follicular thyroid carcinoma model with adenoviral vectors transducing murine interleukin-12.
Zhang R; DeGroot LJ
Endocrinology; 2003 Apr; 144(4):1393-8. PubMed ID: 12639922
[TBL] [Abstract][Full Text] [Related]
3. Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12.
Yamazaki M; Zhang R; Straus FH; Messina M; Robinson BG; Hashizume K; DeGroot LJ
Gene Ther; 2002 Jan; 9(1):64-74. PubMed ID: 11850724
[TBL] [Abstract][Full Text] [Related]
4. An adenoviral vector expressing functional heterogeneous proteins herpes simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma.
Zhang R; DeGroot LJ
Endocr Relat Cancer; 2001 Dec; 8(4):315-25. PubMed ID: 11733228
[TBL] [Abstract][Full Text] [Related]
5. Immune response against medullary thyroid carcinoma (MTC) induced by parental and/or interleukin-2-secreting MTC cells in a rat model of human familial medullary thyroid carcinoma.
Lausson S; Fournes B; Borrel C; Milhaud G; Treilhou-Lahille F
Cancer Immunol Immunother; 1996 Oct; 43(2):116-23. PubMed ID: 8954146
[TBL] [Abstract][Full Text] [Related]
6. Genetic immunotherapy for medullary thyroid carcinoma: destruction of tumors in mice by in vivo delivery of adenoviral vector transducing the murine interleukin-2 gene.
Zhang R; Baunoch D; DeGroot LJ
Thyroid; 1998 Dec; 8(12):1137-46. PubMed ID: 9920370
[TBL] [Abstract][Full Text] [Related]
7. Thyroid cancer immuno-therapy with retroviral and adenoviral vectors expressing granulocyte macrophage colony stimulating factor and interleukin-12 in a rat model.
Tanaka K; Towata S; Nakao K; Mizuguchi H; Hayakawa T; Niwa M; Ishii N; Nagayama Y
Clin Endocrinol (Oxf); 2003 Dec; 59(6):734-42. PubMed ID: 14974915
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for medullary thyroid carcinoma by a replication-defective adenovirus transducing murine interleukin-2.
Zhang R; Minemura K; De Groot LJ
Endocrinology; 1998 Feb; 139(2):601-8. PubMed ID: 9449631
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy of anaplastic thyroid carcinoma with a single-chain interleukin-12 fusion protein.
Shi Y; Parhar RS; Zou M; Baitei E; Kessie G; Farid NR; Alzahrani A; Al-Mohanna FA
Hum Gene Ther; 2003 Dec; 14(18):1741-51. PubMed ID: 14670125
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated tumor-specific combined gene therapy using Herpes simplex virus thymidine/ganciclovir system and murine interleukin-12 induces effective antitumor activity against medullary thyroid carcinoma.
Yamazaki M; Straus FH; Messina M; Robinson BG; Takeda T; Hashizume K; DeGroot LJ
Cancer Gene Ther; 2004 Jan; 11(1):8-15. PubMed ID: 14681722
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy of established medullary thyroid carcinoma with herpes simplex viral thymidine kinase in a rat tumor model: relationship of bystander effect and antitumor efficacy.
Zhang R; DeGroot LJ
Thyroid; 2000 Apr; 10(4):313-9. PubMed ID: 10807059
[TBL] [Abstract][Full Text] [Related]
12. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12.
Bramson J; Hitt M; Gallichan WS; Rosenthal KL; Gauldie J; Graham FL
Hum Gene Ther; 1996 Feb; 7(3):333-42. PubMed ID: 8835220
[TBL] [Abstract][Full Text] [Related]
13. Effective genetic therapy of established medullary thyroid carcinomas with murine interleukin-2: dissemination and cytotoxicity studies in a rat tumor model.
Zhang R; Straus FH; DeGroot LJ
Endocrinology; 1999 May; 140(5):2152-8. PubMed ID: 10218966
[TBL] [Abstract][Full Text] [Related]
14. Treatment of medullary thyroid carcinoma by combined expression of suicide and interleukin-2 genes.
Soler MN; Milhaud G; Lekmine F; Treilhou-Lahille F; Klatzmann D; Lausson S
Cancer Immunol Immunother; 1999; 48(2-3):91-9. PubMed ID: 10414462
[TBL] [Abstract][Full Text] [Related]
15. Construction of vectors expressing bioactive heterodimeric and single-chain murine interleukin-12 for gene therapy.
Lee YL; Tao MH; Chow YH; Chiang BL
Hum Gene Ther; 1998 Mar; 9(4):457-65. PubMed ID: 9525307
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2 and interleukin-4 display potent antitumour activity on rat medullary thyroid carcinoma cells.
Cressent M; Pidoux E; Cohen R; Modigliani E; Roth C
Eur J Cancer; 1995 Dec; 31A(13-14):2379-84. PubMed ID: 8652272
[TBL] [Abstract][Full Text] [Related]
17. Viral mediated gene therapy for the management of metastatic thyroid carcinoma.
DeGroot LJ; Zhang R
Curr Drug Targets Immune Endocr Metabol Disord; 2004 Sep; 4(3):235-44. PubMed ID: 15379725
[TBL] [Abstract][Full Text] [Related]
18. Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity.
Péron JM; Bureau C; Gourdy P; Lulka H; Souque A; Calippe B; Selves J; Al Saati T; Bernad J; Cordelier P; Couderc B; Pradayrol L; Pipy B; Buscail L; Vinel JP
Gut; 2007 Jan; 56(1):107-14. PubMed ID: 16891358
[TBL] [Abstract][Full Text] [Related]
19. Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer.
Chen L; Chen D; Block E; O'Donnell M; Kufe DW; Clinton SK
J Immunol; 1997 Jul; 159(1):351-9. PubMed ID: 9200473
[TBL] [Abstract][Full Text] [Related]
20. Gene therapeutic approaches for medullary thyroid carcinoma treatment.
Drosten M; Pützer BM
J Mol Med (Berl); 2003 Jul; 81(7):411-9. PubMed ID: 12811413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
